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Methods: We retrospectively studied 65 consecutive treatment-naı¨ve patients with 69 EGC le-
sions who were selected to be treated by ESD. A total of 56 lesions (48 CR lesions and 8 non-CR
lesions) were analyzed for local recurrence after ESD.
Results and Discussion: ESD was curative for gastric epithelial tumors in 51 (73.9%) but not in
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rence. None of the patients died from gastric cancer-associated diseases during follow-up. In
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96 Y.-Y. Hsieh et al.Conclusion: ESD offers good outcome after treatment for EGC. To decrease the risk of local
recurrence, preoperative diagnosis of tumor extent and accurate postoperative pathological
evaluation are very important.
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Early gastric cancer (EGC) is defined as a cancer confined to
the mucosal or the submucosal (SM) layer, irrespective of
lymph nodemetastases (T1, any N) [1]. The incidence of EGC
varies among different countries. Interestingly, the rate of
gastric cancer in Japan is> 50% [2], whereas the rate is< 5%
in the West [3]. The reason for this difference in incidence
rate between Japan and the West may be due to diagnostic
discrepancy, becausemucosal cancer, as defined in Japan, is
often diagnosed as dysplasia in the West. However, this sit-
uation is gradually resolving after pathologists reached a
consensus at a meeting held in Vienna [4].
According to the guidelines of International and Japa-
nese Gastric Cancer Associations [5], indications for endo-
scopic mucosal resection (EMR) are differentiated
adenocarcinoma, intramucosal cancer, lesions < 20 mm,
and depressed lesions without ulceration or scarring.
However, these aforementioned criteria may be too strict
to avoid unnecessary surgery. Based on the analysis of the
risk of lymph node involvement in EGC, Gotoda et al [6]
proposed extended criteria for endoscopic resection in
the endoscopic SM dissection (ESD) era, which include the
following: mucosal cancers without ulcer, regardless of
lesion size; mucosal lesions with ulcer < 30 mm; minute (<
500 mm from the muscularis mucosae) SM invasive
cancers < 30 mm. Isomoto et al [7] reported no difference
in outcomes between treatments based on the aforemen-
tioned guideline and the expanded criteria [7].
Aims
The ESD technique was first developed in Japan [8] and has
become the treatment of choice for endoscopic resection
of EGC. In previous long-term follow-up studies, risk factors
for local recurrence, such as EGC location, EGC size, com-
plete resection rate, and pathological diagnosis after ESD
(poorly differentiated adenocarcinoma and EGC invasion
depth) have been discussed. However, only limited data are
available on the interval of disease-free status after ESD for
EGC in Taiwan [9]. In this long-term follow-up study, we
analyzed the risk factors that affect the local recurrence
and noncurative resection (non-CR) of lesions during 2e105
months of follow-up after ESD.
Methods
Patients
The patients were enrolled based on the guideline criteria
for EMR and expanded criteria for ESD, as described earlier[5,6]. Patients with an EGC who did not fall into these
categories were excluded from the study and received
gastrectomy with lymph node removal. We retrospectively
studied 162 consecutive treatment-naı¨ve patients with
gastric neoplasm for whom the Department of Gastroen-
terology (Chang Gung Memorial Hospital, Chiayi, Taiwan)
had recommended ESD treatment between August 2004 and
December 2009. After excluding the benign lesions ac-
cording to the pathological report of specimens, 65
consecutive treatment-naı¨ve patients with 69 EGC lesions
were selected. The study protocol was approved by the
Clinical Research Committee of the Chang Gung Memorial
Hospital. The diagnosis of EGC was confirmed by patho-
logical examination. We only included EGCs with a patho-
logical result confirming high-grade dysplasia, carcinoma in
situ, or adenocarcinoma. The clinical data were reviewed,
and the following parameters were recorded: sex, age,
location, macroscopic appearance, biopsy result, patho-
logical result, endoscopic ultrasonography finding, EGC
size, specimen size, procedure time, hospital stay,
complication, endoscopic follow-up period, local recur-
rence status, and survival status.
ESD technique
ESD was performed after the patients were sedated with
midazolam titration. The procedure began with the iden-
tification of the lesion and marking a zone 5e10 mm
outside the margin of the target lesion with a precut nee-
dle knife (CD-1L; Olympus) and electrosurgical coagulation
current (forced coagulation, 20 W). The electrosurgical
unit ERBE ICC 350 (ERBE Elektromedizin, Tu¨bingen, Ger-
many) was used for this purpose. Glycerol (10%), diluted
epinephrine (1:100,000), and diluted indigo carmine were
then injected into the SM layer to lift the mucosa. An initial
incision was made with a conventional needle knife. Next,
a circumferential mucosal incision was made around the
lesion using an insulated-tip knife (IT knife) with an elec-
trosurgical current (Endocut mode, effect 3, 80 W). Lesions
were completely removed by SM dissection using an IT
knife.
Histopathological evaluation
All resected specimens were flattened and fixed in formalin
solution. The fixed specimens were sectioned into 2-mm-
thick slices and classified by a pathologist according to the
Vienna classification [4]. The sizes of the resected speci-
mens were measured at the greatest width of the lesion.
The resected margin and depth of tumor invasion were
observed carefully and recorded.
Table 1 Clinical characteristics of 65 patients with 69
gastric epithelial neoplasms who underwent ESD.a
Male/female 39/26
Age (y) 67.3  12.7 (36e85)
Lesion’s location
Upper third/middle
third/lower third
8/8/53
AW/PW/LC/GC 18/15/28/8
Lesion’s macroscopic
appearance
I/IIa/IIb/IIc/IIa þ IIc 12/23/2/6/26
Ulcer (þ/e) 37/32
Lesion size (mm; pre-ESD’s
lesion size)
19.0  11.0 (5e70)
Pre-ESD biopsy result
Adenocarcinoma 18
High-grade dysplasia or
carcinoma in situ
26
Adenomatous polyp 3
Intestinal metaplasia 1
Resected specimen size (mm) 32.4  11.8 (10e72)
(post-ESD’s specimen size)
Pathological result
High-grade dysplasia or
carcinoma in situ
49
Adenocarcinoma 20
Well/poorly differentiated 6/14
EUS depth (M/SM/NA) 43/7/19
Pathological depth (M/SM/MP) 65/2/2
Procedure duration (min) 85.5  63.4 (12e360)
Hospital stay (d) 4.8  2.8 (1e13)
Data are expressed as mean  standard deviation.
AW Z anterior wall; EGC Z early gastric cancer;
ESD Z endoscopic submucosal dissection; GC Z greater cur-
vature; LC Z lesser curvature; M Z mucosa; MP Z muscularis
propria; NA Z not available; PW Z posterior wall;
SM Z submucosa.
a Endoscopic ultrasonography (EUS) was not performed in
every case because the EGC’s depth can be predicted only by
EGD in some cases.
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Major bleeding was defined as a hemoglobin decrease of >
2 mg/dL following the procedure. Perforation was diag-
nosed endoscopically during the procedure as free air on a
plain abdominal radiograph.
Patient follow-up
The follow-up program consisted of physical examination,
laboratory blood test, endoscopy, and/or ultrasound 2
months, 6 months, and 12 months after the ESD to assess
the completeness of the resection in the 1st year; there-
after, it was examined annually to detect local recur-
rence. Biopsy was repeated for histopathological
evaluation when tumor recurrence was suspected. For a
recurrent EGC case, the recurrence location was carefully
compared with the original location. “Recurrence” was
defined as newly developed EGC after initial complete
resection at the same location as the original; “meta-
chronous lesion” was defined as newly developed EGC in a
different location; and “synchronous lesion” was defined
as the presence of two EGC lesions in different locations at
the same time.
Statistical evaluation
Statistical analysis was performed using SPSS software
version 12.0 (SPSS Inc., Chicago, IL, USA). Patient charac-
teristics were represented as the mean  standard devia-
tion. Long-term disease-free status data were analyzed by
the KaplaneMeier method with significance based on Wil-
coxon (Gehan) test and with median survival time indi-
cated. Comparisons of risk factors that affect complete
resection were calculated by the Chi-square (Pearson) test.
Results
The demographic characteristics of the 65 patients with 69
lesions who were scheduled to receive treatment by ESD for
gastric epithelial cancers are presented in Table 1. Our
patient cohort included 39 men and 26 women with a mean
age of 67.3 years. The majority of the tumors were located
in the lower (nZ 53) stomach. Most cancers were classified
as “flat, elevated superficial cancer, type IIa” (nZ 23) and
“IIa þ IIc” (n Z 26) by endoscopic morphological classifi-
cation. The mean diameter of the tumors was 1.90 cm,
whereas that of the resected specimens was 3.24 cm. The
depth of the gastric epithelial cancers was evaluated after
pathological assessment: 65 early cancers were limited to
the mucosal layer, two to the SM superficial layer, and two
to the muscularis propria layer.
Three cases with initial diagnosis (pre-ESD biopsy result)
as adenomatous polyp turned to be cases of severe
dysplasia (n Z 2) and carcinoma in situ (n Z 1) after ESD.
One case with initial diagnosis as intestinal metaplasia
turned out to be carcinoma in situ. According to the final
pathological classification, the majority of EGCs resected
were high-grade dysplasias (n Z 49) or adenocarcinomas
(n Z 20).The mean operation time was 85.5 minutes (range,
12e360 minutes) and the mean length of stay was 4.8 days
(range, 1e13 days). The complications after ESD are pre-
sented in Table 2.
In the intention-to-treat group (69 lesions), the proce-
dure had to be changed to operative treatment due to
suspected SM invasion (because of severe fibrosis of the
submucosa) in five (7.25%) cases; obscured endoscopic view
in one (1.45%) case with massive bleeding (Table 2). Four
(5.80%) patients had major bleeding post-ESD and three
patients even needed a second intervention after the ESD
procedure. Two (2.90%) patients had perforation during
ESD; one patient underwent closure by hemoclip and the
other received emergency surgery. The cancers in these
two cases were 1.0- and 7.0-cm intramucosal lesions. The
perforations were located high in the body and had SM
fibrosis changes.
“Curative treatment” was defined as a one-piece
resection with at least 1-mm cancer-free margins,
Table 2 Complications after ESD.
Complications 11 (15.9)
Failure due to severe fibrosis of SM 5 (7.2)
Perforation due to severe fibrosis of SM 2 a
MP layer involvement 3 a
Failure due to endoscopic view
obscured by bleeding
1 (1.4)
Put on hold due to suspected
perforation, repeat ESD 1 mo later
1 (1.4)
Major bleeding (hemoglobin
decrease > 2 mg/dL)
4 (5.8)
Recurrent bleeding requiring
another EGD for hemostasis
3 a
Data are presented as n (%).
ESD Z endoscopic submucosal dissection; MP Z muscularis
propria; SMZ submucosa; EGDZ esohago-gastro-duodenoscopy.
a Cases included.
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involvement, and cancer depth limited to the SM superficial
layer (< 500 mm to the muscular muscle layer) after path-
ological assessment. For gastric epithelial cancers, 51
(73.9%) patients had curative treatment with ESD and 18
(26.1%) patients had noncurative treatment with ESD
(Fig. 1). Of the 18 noncurative lesions, eight received en
bloc resection along the margin of the cancer and five had
deep-margin involvement. These eight patients were
advised to undergo additional surgery. One of these wasFigure 1 A flow diagram of treatment of the 69 early gastric
resection also received argon plasma coagulation to destroy the resi
E()Z no en bloc resection; EMRZ endoscopic mucosal resection;
without margin involvement.lost to follow-up and the remaining seven refused surgery
because of comorbidity with major systemic diseases, such
as congestive heart failure and chronic renal insufficiency.
Patients without CR further received argon plasma
coagulation (APC) to destroy the residual tumor. The long-
term follow-up analysis was divided into the following two
subgroups: CR group and non-CR group. The characteristics
of the two groups are presented in Tables 3 and 4. Finally,
data on 56 patients were collected for local recurrence rate
analysis, as shown in Fig. 1.
The cumulative local recurrence rates were 5.3% in the
CR group and 56.7% in the non-CR group (p Z 0.0091;
Fig. 2). The disease-free status was high (94.7%) with CR.
Furthermore, in the CR group (48 patients), the risk factor
affecting the disease-free status was analyzed and no sig-
nificant factor was identified (data not shown in the figure).
Among the patients with local recurrence (2/48 in the CR
group and 3/8 in the noncurative group), one underwent
surgery, one was lost to follow-up, and three underwent
repeat ESD; of these three patients, one received addi-
tional ESD when recurrence was noted at the 38th month
and 64th month. No recurrence was noted at the 3-month
follow-up period and all were free of recurrence at the
time of this writing, as shown in Table 4. None of the pa-
tients died of gastric cancer-associated diseases during the
follow-up period.
The risk factors that affect the non-CR are tumor loca-
tion (p Z 0.013), deeper invasion (p < 0.001), undifferen-
tiated histopathology (p < 0.001), and ulcer presence
(p Z 0.045), as shown in Table 5.cancer (EGC) lesions in this study. Patients without curative
dual tumor. CRZ curative resection; E(þ)Z en bloc resection;
M(þ)Z specimen with margin involvement; M()Z specimen
Table 3 Characteristics of the 48 early gastric cancer lesions after curative resection.
48 lesions (46 patients) after curative resection (CR group)
Synchronous (1 patient, N Z 1)
Because of the different locations of the 2 lesions occurring at the same time in the same patient, we excluded the 2nd lesion
as treatment was shifted to EMR due to difficulty in dissecting the lesion owing to its location.
Metachronous (1 patient, N Z 2)
The lesions received ESD because they had different locations and occurred at different times in the same patient.
Local recurrence (2 patients, N Z 3)
1 patient received additional ESD at the 20th mo. Thereafter, no recurrence during 23 months’ follow-up period (N Z 2, the
lesion after ESD was a new one).
1 patient received additional EMR due to severe SM fibrosis at the 9th mo (N Z 1, because we excluded the second lesion as
treatment was shifted to EMR).
42 patients, N Z 42
42 patients with one lesion, without synchronous, metachronous, or local recurrence.
CR Z curative resection; EMR Z endoscopic mucosal resection; ESD Z endoscopic submucosal dissection; SM Z submucosal.
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EGC has a good prognosis with long-term survival rates as
high as 95% after gastrectomy with removal of lymph nodes
[10]. Follow-up studies are required to confirm whether
endoscopic treatment can be an alternative treatment
choice for EGC and whether its efficacy is similar to that of
conventional surgery. In a previous study, Chang et al [9]
reported a short-term outcome of ESD for gastric epithe-
lial tumor in Taiwan. Here, we have presented the long-
term follow-up outcome results.
EMR can achieve complete resection in the case of some
EGCs; however, local recurrence occasionally occurs [11].
In a conventional EMR, incomplete and piecemeal re-
sections are the main reasons for local recurrences, which
often occur in lesions > 2 cm, depressed lesions, and those
in difficult-to-access locations [12]. In addition, piecemeal
resection of the lesions makes it difficult for a pathologist
to diagnose and confirm the staging. En bloc resection of
ESD provides much higher complete resection rates than
piecemeal resections of EMR. In the event of SM invasion,
muscularis propria invasion, or severe fibrosis in SM thatTable 4 Characteristics of the eight EGC lesions after noncurat
8 lesions (7 patients) after noncurative resection (non-CR group)
E(), M() (1 patient, N Z 1)
Because of severe fibrosis, APC was applied to destroy the resi
E(þ), M(þ) (6 patients, N Z 7)
Synchronous (1 patient, N Z 2)
Because the 2 lesions occurred at different locations at the sa
suspected residual tumor; no recurrence during 17 mo follow
Local recurrence (3 patients, N Z 3)
1 received surgery after 3 mo follow-up; EGD revealed recur
1 patient was lost to follow-up after recurrence at the 31st m
1 received additional ESD (twice) at the 38th mo and 64th mo
time of writing.
Two patients, N Z 2
2 patients with 1 lesion, without synchronous, metachronous
APCZ argon plasma coagulation; CRZ curative resection; E()Z no
submucosal dissection; M() Z specimen without margin involvemencannot always be predicted prior to ESD, the initial plan to
perform ESD is usually shifted to EMR.
In this study, the en bloc and CR rates were 85.5% and
73.9%, respectively, which are relatively lower than those
of other study [13]. The reason may be due to the small
case numbers in our study, which can overweigh the failure
part.
In the intention-to-treat group (69 lesions), we included
the ESD failure and incomplete resection cases because of
the shift to the EMR method. In addition, we also included
patients who refused further operative treatment to find
out the incidence of the complication (Table 2) and eval-
uate whether the risk factors affect CR or not (Table 5).
In our daily practice, we found that some patients do not
prefer further surgical procedure. The coagulation mode
was applied to stop the easy bleeding tendency while SM
invasion occurred or APC was applied to destroy the resid-
ual tumor site for the non-CR cases. However, due to the
burn effect of coagulation, the margin of the pathological
specimens could not be well evaluated. In this study, the
cumulative local recurrence rates were 5.3% in the CR
group and 56.7% in the non-CR group (p Z 0.0091; Fig. 2).ive resection.
dual tumor; no recurrence during 91 mo follow-up period.
me time in the same patient, APC was applied to destroy the
-up period.
rence.
o.
recurrence; no recurrence during 3 mo of follow-up until the
, or local recurrence.
en-bloc resection; EGCZ early gastric cancer; ESDZ endoscopic
t.
Figure 3 The cumulative disease-free status of early gastric
cancer lesions (n Z 48) that underwent curative endoscopic
submucosal dissection. The disease-free status was 94.7%.Figure 2 Comparison of local recurrence rate in early gastric
cancer lesions that underwent endoscopic submucosal dissec-
tion [56 lesions; categorized by whether or not they received
curative resection(CR)]. The cumulative local recurrence rates
were 5.3% in the CR group and 56.7% in the non-CR group in the
84th month [calculated by the Wilcoxon (Gehan) statistical
method, p Z 0.009].
100 Y.-Y. Hsieh et al.Therefore, we should always emphasize the importance of
regular follow-up, especially for noncurative cases.
The disease-free status was high (94.7%) with CR, as
shown in Fig. 3. After excluding the factors affecting non-
CR lesions in the CR group (n Z 48 lesions), no other risk
factor was significant in the disease-free status analysis.
In a previous study, Takenaka et al [14] reported that
tumor size (> 30 mm) and tumor location (upper 3rd) were
significant predictors of local recurrence after ESD. In this
study, for the intention-to-treat group (69 lesions), the non-
CR lesions significantly increased local recurrence risk. The
risk factors for non-CR are tumor location (p Z 0.013) and
tumor size ( 2 cm; p Z 0.055, Table 5)
The rate of lymph node metastasis from EGC was re-
ported to be 0.4% in differentiated mucosal cancers and
4.2% in undifferentiated mucosal cancers [15]. This differ-
ence is an important criterion to select patients for ESD. In
addition, undifferentiated EGC is more likely to invade theTable 5 Risk factors that affect noncurative resection.a
Risk factor p
Location: PW 0.204
Location: low 0.013
Ulcer 0.045
Poorly differentiated adenocarcinoma <0.001
Invasion depth (mucosal or submucosal) <0.001
Tumor size ( 2 cm) 0.055
Skill mature (Case  20th) 0.180
PW Z posterior wall.
a Comparisons of risk factors were calculated by the Chi-
square (Pearson) statistical method.SM layer, even for tumors that are small. Undifferentiated
EGCs are often distributed in a discontinuous pattern. This
also makes it difficult to define a definite margin of a lesion
prior to ESD. In our study, the non-CR significantly increased
local recurrence risk, and was significantly higher for le-
sions having deeper invasion (p < 0.001) and those having
an undifferentiated histopathology (p < 0.001; Table 5).
In conclusion, ESD offers a good outcome after EGC
treatment [16,17]. To decrease the risk of local recurrence,
preoperative diagnosis of the tumor extent (e.g., SM inva-
sion and tumor margin positivity) and accurate post-
operative pathological evaluation (e.g., resection margin)
and close follow-up are very important.
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